Department of Biotechnology, Gui-Lin Medical University, 541004 China.
Expert Rev Proteomics. 2009 Oct;6(5):551-61. doi: 10.1586/epr.09.72.
Tumor proteomics apply proteomics techniques to tumor biological research, mainly by screening candidate biomarkers for early tumor diagnosis, prognosis and treatment. Hepatocellular carcinoma (HCC) is a type of malignant tumor with one of the highest death rates in the world. With the advent of the post-genomic age, tumor biological research developing the technology of proteomics has become a major focus of researchers. The discovery of novel candidate biomarkers is one of crucial problems for the early diagnosis of HCC. In general, there are three distinct types of candidate biomarkers for HCC based on different areas: biochemical biomarkers, antigenic biomarkers and epigenetic biomarkers. This review mainly discusses current advances in the problems and prospects of candidate biomarker for the early diagnosis of HCC, discovered by technologies of tumor proteomics.
肿瘤蛋白质组学将蛋白质组学技术应用于肿瘤生物学研究,主要通过筛选候选生物标志物用于早期肿瘤诊断、预后和治疗。肝细胞癌 (HCC) 是一种恶性肿瘤,其死亡率在世界范围内位居前列。随着后基因组时代的到来,肿瘤生物学研究中蛋白质组学技术的发展已成为研究人员关注的重点。新型候选生物标志物的发现是 HCC 早期诊断的关键问题之一。一般来说,基于不同领域,HCC 的候选生物标志物有三种不同类型:生化标志物、抗原标志物和表观遗传标志物。本综述主要讨论了肿瘤蛋白质组学技术发现的 HCC 早期诊断候选生物标志物的问题和前景。